Abstract
PURPOSE There has been considerable controversy regarding susceptibility of adolescents (10-19 years) and youth (15-24 years) to COVID-19. However, a number of studies have reported that adolescents are significantly less susceptible than older adults. Summer 2020 provided an opportunity to examine data on prevalence since after months of lockdowns, with the easing of restrictions, people were mingling, leading to surges in cases.
METHODS We examined data from six U.S. states experiencing surges in the number of cases to determine prevalence of COVID-19, and two other measures, related to prevalence in adolescents and youth as compared to older adults. The two other measures were: (Percentage of cases observed in a given age group) ÷ (percentage of cases expected based on population demographics); and percentage deviation, or [(% observed - % expected)/ % expected] x 100.
RESULTS Prevalence of COVID-19 for adolescents and for youth was significantly greater than for older adults (p<.00001), as was percentage observed ÷ percentage expected (p<.005). The percentage deviation was significantly greater in adolescents/youth than in older adults (p < 0.00001) when there was an excess of observed cases over what was expected, and significantly less when observed cases were fewer than expected (p< 0.00001).
CONCLUSIONS Our results are contrary to previous findings that adolescents are less susceptible than older adults. The findings have implications for school re-openings. The age groups 10-19 and 15-24 are students in middle school, high school, college, and the first two years of professional/graduate school. The high prevalence in these age groups would argue against school re-openings in the near future.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was secured for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study is exempt. Data are de-identified data from the six states' Department of Health websites.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is available at the listed URLs.
https://floridahealthcovid19.gov/
https://www.tn.gov/content/tn/health/cedep/ncov/data.html
http://mophep.maps.arcgis.com/apps/MapSeries/index.html?appid=8e01a5d8d8bd4b4f85add006f9e14a9d
https://www.coronavirus.kdheks.gov/160/COVID-19-in-Kansas
https://coronavirus.utah.gov/case-counts/
https://doh.sd.gov/news/coronavirus.aspx
http://edr.state.fl.us/Content/populationdemographics/data/Pop_Census_Day.pdf
https://healthapps.dhss.mo.gov/MoPhims/QueryBuilder?qbc=PNM&q=1&m=1
https://gardner.utah.edu/wp-content/uploads/State-of-Utah-Demographic-Profile-2010-2018.pdf
